Liselotte Coorevits1, Ans Traen2, Luk Bingé2, Patrick Descheemaeker3, Jerina Boelens4, Marijke Reynders3, Elizaveta Padalko5. 1. Department of Laboratory Medicine, Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium; Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Corneel Heymanslaan 10, 9000 Ghent, Belgium. Electronic address: liselotte.coorevits@ugent.be. 2. PASOP VZW, Brabantdam 100, 9000 Ghent, Belgium. 3. Department of Laboratory Medicine, AZ St Jan Bruges, Ruddershove 10, 8000 Bruges, Belgium. 4. Department of Laboratory Medicine, Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium; Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Corneel Heymanslaan 10, 9000 Ghent, Belgium. 5. Department of Laboratory Medicine, Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium; Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Corneel Heymanslaan 10, 9000 Ghent, Belgium; School of Life Sciences, Hasselt University, Agoralaan D, 3590 Diepenbeek, Belgium.
Abstract
OBJECTIVES: Mycoplasma genitalium is emerging as an aetiological agent of sexually transmitted infections (STIs). Although M. genitalium is commonly treated with azithromycin, macrolide resistance associated with point mutations in the 23S rRNA gene is emerging. METHODS: In this study, the prevalence of M. genitalium and macrolide resistance in female sex workers (FSW) in Belgium was evaluated by a prospective study conducted between 2015 and 2016. Vaginal swabs were sampled from 303 FSW who underwent testing for M. genitalium along with standard STI screening. All samples positive for M. genitalium were subsequently tested for mutations associated with macrolide resistance. RESULTS: M. genitalium was detected in 10.8% of participants and macrolide resistance-associated mutations (A2058G and A2059G) were found in 6.5% of isolates. CONCLUSIONS: M. genitalium is clearly present in FSW in Belgium. In contrast to other reports, for now the occurrence of macrolide resistance appears limited in this specific target population.
OBJECTIVES:Mycoplasma genitalium is emerging as an aetiological agent of sexually transmitted infections (STIs). Although M. genitalium is commonly treated with azithromycin, macrolide resistance associated with point mutations in the 23S rRNA gene is emerging. METHODS: In this study, the prevalence of M. genitalium and macrolide resistance in female sex workers (FSW) in Belgium was evaluated by a prospective study conducted between 2015 and 2016. Vaginal swabs were sampled from 303 FSW who underwent testing for M. genitalium along with standard STI screening. All samples positive for M. genitalium were subsequently tested for mutations associated with macrolide resistance. RESULTS:M. genitalium was detected in 10.8% of participants and macrolide resistance-associated mutations (A2058G and A2059G) were found in 6.5% of isolates. CONCLUSIONS:M. genitalium is clearly present in FSW in Belgium. In contrast to other reports, for now the occurrence of macrolide resistance appears limited in this specific target population.
Authors: Laura C Chambers; Jørgen S Jensen; Jennifer L Morgan; M Sylvan Lowens; Sarah S Romano; Patricia A Totten; Olusegun O Soge; James P Hughes; Matthew R Golden; Lisa E Manhart Journal: Sex Transm Dis Date: 2019-12 Impact factor: 2.830
Authors: Simon C Masha; Piet Cools; Patrick Descheemaeker; Marijke Reynders; Eduard J Sanders; Mario Vaneechoutte Journal: BMC Infect Dis Date: 2018-11-06 Impact factor: 3.090
Authors: Matthias T Buhmann; Dominik Abt; Oliver Nolte; Thomas R Neu; Sebastian Strempel; Werner C Albrich; Patrick Betschart; Valentin Zumstein; Antonia Neels; Katharina Maniura-Weber; Qun Ren Journal: Microbiome Date: 2019-04-13 Impact factor: 14.650